India, May 30 -- Summit Therapeutics Inc. (SMMT) announced Friday positive topline results from the Phase III clinical trial, HARMONi, evaluating ivonescimab plus chemotherapy in patients with EGFR-Mutant non-small cell lung cancer or NSCLC.
Based on the results of the HARMONi clinical trial, Summit said it intends to file a Biologics License Application or BLA in order to seek approval for ivonescimab plus chemotherapy in this setting.
The company noted that the first global Phase III study evaluating ivonescimab plus chemotherapy showed statistically significant and clinically meaningful improvement in progression-free survival or PFS primary endpoint and showed a positive trend in the other primary endpoint, overall survival.
The U.S....